Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Lung megakaryocytes and lung megakaryocyte-derived platelets contribute to lung injury

Award Number: R03HL183281
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2026
PERIOD OF PERFORMANCE END DATE: 05/31/2028

Group Awards By:

View Award Description

Lung megakaryocytes and lung megakaryocyte-derived platelets contribute to lung injury - Platelets are key cells involved in coagulation and have been recognized as effector immune cells with significant contributions to infectious and inflammatory syndromes. While capable to de novo protein synthesis, platelets are anucleate and must have mRNA invested into them by a parent megakaryocyte prior to being released into circulation. We have previously shown that bone megakaryocytes alter the transcriptome of circulating platelets in a mouse model of sepsis. My NHLBI K08 focused on the role of FcγRIIA, a low affinity IgG immune receptor, impacted platelets function in sepsis. We have found that FCGR2A transcript was one of the most differentially expressed transcripts in platelets from patients with sepsis. I aimed to interrogate how FcγRIIA upregulation impacted platelet function and increased sepsis-induced mortality. After my K award was initiated the COVID-19 pandemic shuttered all research with the exception of those studies that were directly related to COVID-19. I quickly pivoted my research towards investigating the impact of acute COVID-19 infection on the platelet transcriptome and alterations in platelet function. During the COVID-19 pandemic we found that the platelet transcriptome was significantly altered in those patients with acute hypoxemic respiratory failure. Furthermore, we found that platelets and neutrophil extracellular traps (NETs) were found in small lung vessel of patients deceased from COVID-19. We found plasma markers of NETs were significantly correlated with severity of respiratory failure and mortality. Suggesting that immunothrombosis is a significant contributor to hypoxemic respiratory failure. Sepsis is the most common cause of acute hypoxemic respiratory failure, termed acute respiratory distress syndrome (ARDS). ARDS is a common cause of ICU admission that continues to carry significant morbidity and mortality. Moreover, others have shown that megakaryocytes are found in both the lung and the spleen and produce platelets that express markers suggesting an immune phenotype. We hypothesized that the population of megakaryocytes found in the lung will contribute to lung injury. We have found that lung megakaryocytes are present and produce platelets in a murine model of LPS- induced acute lung injury. We aim to study how both the lung megakaryocyte and lung megakaryocyte-derived platelet increase both early and late-stage lung injury.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $231,000 )
2026	2026	UNIVERSITY OF UTAH	201 PRESIDENTS CIR	SALT LAKE CITY	UT	84112	SALT LAKE	USA	Lung Diseases Research	000	1	5/28/2026	NEW	$231,000
														Subtotal = $231,000

Grand Total All Awards = $231,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Lung megakaryocytes and lung megakaryocyte-derived platelets contribute to lung injury

Award Number: R03HL183281

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2026

PERIOD OF PERFORMANCE END DATE: 05/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer